Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
2 Stocks That Could Turn $100 Into $1,000 by 2028
07:15am, Sunday, 22'nd Jan 2023
These growth stocks have substantial tailwinds.
Is Vir Biotechnology (VIR) Outperforming Other Medical Stocks This Year?
11:17am, Friday, 20'th Jan 2023
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.
Vir Biotechnology: High Potential Returns With High Volatility Risks
02:59am, Thursday, 19'th Jan 2023
Vir Biotechnology is a commercial-stage immunology company that bases its activity on infectious disease prevention. The agreement with GSK made it possible to obtain large revenues and profits in 202
Vir Biotechnology: The First Entry In My Long Term Value Portfolio
03:25am, Sunday, 08'th Jan 2023
Today, I explain why I've taken a position in VIR, including going over its pipeline, partners, and anticipated milestones. I then look at the company's valuation and cash position as well as Seeking
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Vir Biotechnology: A 'Magic Formula' Top Performer
05:30pm, Thursday, 22'nd Dec 2022
Joel Greenblatt (Trades, Portfolio), the manager of Gotham Capital, has what he calls a “Magic Formula” for investing. First detailed in "The Little Book That Beats the Market," this formula is ba
Vir Biotechnology: Collaborative Approach To Taking On Serious Diseases
08:44am, Saturday, 17'th Dec 2022
Vir Biotechnology is currently profitable with record breaking revenues, but performance is linked to unsustainable COVID-fueled sales results. Although sales are predicted to decline in 2023, the com
2 Fast-Growing Healthcare Stocks to Buy and Hold
07:10am, Friday, 02'nd Dec 2022
The innovative companies have made great gains in a short period of time.
Should Value Investors Buy Vir Biotechnology (VIR) Stock?
11:17am, Tuesday, 22'nd Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
5 Winning Stocks Backed by the Overlooked Rising P/E Trick
09:02am, Monday, 21'st Nov 2022
Want to try an out-of-the-box approach? Tap AMC Entertainment (AMC), Live Nation Entertainment (LYV), CuriosityStream (CURI), Helius Medical Technologies (HSDT) and Vir Biotechnology (VIR).
VIR Biotech CEO on its positive Covid antibody drug results
09:36am, Saturday, 19'th Nov 2022
CNBC's Meg Tirrell discusses VIR Biotechnology's antibody drug results and what it can do to aid the Covid pandemic with VIR Biotech CEO George Scangos.
Wall Street Analysts Predict a 107% Upside in Vir Biotechnology, Inc. (VIR): Here's What You Should Know
02:55pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 107.4% in Vir Biotechnology, Inc. (VIR). While the effectiveness of this highly sought-after metric is question
Are Investors Undervaluing Dynavax Technologies (DVAX) Right Now?
02:40pm, Tuesday, 08'th Nov 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
08:07am, Monday, 07'th Nov 2022 Benzinga
Gainers
Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
03:35pm, Sunday, 06'th Nov 2022 GlobeNewswire Inc.
– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals –
